News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

MacroGenics, Inc. (MGNX) Presents Pre-Clinical Data Demonstrating Potent Activity With Colorectal Cancer Product Candidate MGD007 At The American Association for Cancer Research Annual Meeting


4/7/2014 8:41:12 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

ROCKVILLE, Md., April 6, 2014 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and identifying innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases, today announced the presentation of pre-clinical data demonstrating that MGD007, a dual-affinity re-targeting (DART®) protein, has potent activity against colorectal cancer cells both in vitro and in vivo. The data were presented at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES